All News

Found 757,483 articles

• Kyocera Develops New “Contactless Intelligent Millimeter-Wave Sensing System”

  2/2/2023

  Kyocera Corporation (President: Hideo Tanimoto) today announced it has developed a new “contactless intelligent millimeter-wave sensing system”.

• Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318

  2/2/2023

  Exscientia plc (Nasdaq: EXAI) today announced that EXS4318 ('4318) a compound precision designed by Exscientia and in-licensed by Bristol Myers Squibb in August 2021, has entered Phase 1 clinical trials in the United States.

• Thermo Fisher Scientific to Power All Current U.S. Sites With 100 Percent Renewable Electricity

  2/2/2023

  Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it will power all of the company’s current U.S. sites with 100 percent renewable electricity by 2026.

• KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 2, 2023

  2/2/2023

  KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted two newly-hired employees inducement options to purchase an aggregate of 14,000 shares of KalVista common stock on February 1, 2023 as inducements material to each employee entering into employment with KalVista.

• Oligomerix Announces First-in-Human Dosing of Tau Self-Association Inhibitor OLX-07010

  2/2/2023

  Oligomerix, Inc. today announced the dosing of its first subjects in the company’s Phase 1a clinical trial evaluating lead candidate OLX-07010.

• Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results

  2/2/2023

  Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2022.

• Volta Medical Announces Completion of Patient Enrollment in TAILORED-AF Clinical Trial for Treatment of Atrial Fibrillation

  2/2/2023

  Volta Medical today announced the completion of patient enrollment in the randomized controlled clinical trial, TAILORED-AF, evaluating VX1-guided ablation compared to a ‘standard of care’ anatomical ablation approach.

• Singular Genomics Joins the 10x Genomics Compatible Partner Program

  2/2/2023

  Singular Genomics Systems, Inc. today announced its G4 Sequencing Platform demonstrated compatibility with the 10x Genomics’ Chromium Single Cell platform through the 10x Compatible Partner Program (CPP).

• Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial

  2/2/2023

  Anavex Life Sciences Corp. today announced the total enrollment of 92 patients with Rett syndrome for the ANAVEX®2-73 ( blarcamesine ) EXCELLENCE Phase 2/3 study in Rett syndrome patients ages ≥ 5 years to 17 (inclusive).

• Tonix Pharmaceuticals Announces Acquisition of Preclinical Infectious Disease Portfolio from Healion Bio, Inc.

  2/2/2023

  Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced an agreement whereby Tonix has acquired all of the assets of Healion Bio, Inc. (Healion) including its entire portfolio of next-generation antiviral technology assets.

• Vetter’s Clinical Facility Demonstrates Success with Five Client Products Now on the Market

  2/2/2023

  Both the US Skokie and European Rankweil sites address customer needs in early-phase drug development

• PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX™ (Ketamine) for the Treatment of Rett Syndrome

  2/2/2023

  PharmaTher Holdings Ltd. today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation to KETARX™ (racemic ketamine) for the treatment of Rett Syndrome, a rare genetic neurological disorder.

• ROSALIND FRANKLIN UNIVERSITY STARTUP PREPARING FOR FDA IND FILING AND A PIVOTAL CLINICAL TRIAL ON NOVEL THERAPY FOR SUDDEN CARDIAC ARREST

  2/2/2023

  Rosalind Franklin University of Medicine and Science (RFU) announced today that one of its early-stage companies — Resuscitation Therapeutics (RTx), which is focused on developing new therapies for life-threatening acute cardiovascular events — is preparing an Investigational New Drug (IND) application for submission to the U.S. Food and Drug Administration proposing a novel treatment for sudden cardiac arrest (SCA).

• Virax Biolabs' CEO James Foster Issues Letter to Shareholders

  2/2/2023

  Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), today announced that Mr. James Foster , Chief Executive Officer of Virax, has issued a letter to shareholders.

• Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis

  2/2/2023

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MMP7, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce the expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic pulmonary fibrosis (IPF).

• Phase IIb Clinical Study of Investigational Compound Elinzanetant Evaluated Efficacy and Safety in Postmenopausal Patients with Vasomotor Symptoms Study Findings Published in Menopause: The Journal of The North American Menopause Society

  2/2/2023

  Menopause: The Journal of the North American Menopause Society today published “Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1),” detailing the results of the SWITCH-1 clinical trial aimed at identifying effective dosing for the investigational compound elinzanetant, a non-hormonal, selective neurokinin 1,3 receptor antagonist.

• First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic FibrosisPatient dosing expected to begin in mid-February with topline data anticipated by mid-2023

  2/2/2023

  First Wave BioPharma, Inc. today announced that the first patient was screened for the Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery formulation of adrulipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF).

• Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD

  2/2/2023

  Psycheceutical Bioscience, Inc. (OTCPK: BWVI) ("Psycheceutical" or the "Company") is pleased to announce it has completed its pre-Investigational New Drug ("IND") meeting with the U.S. Food and Drug Administration (FDA) and received positive feedback regarding the Company's development plans for a novel NeuroDirect™ topical formulation of ketamine, intended for treating post-traumatic stress disorder (PTSD).

• Varian Receives FDA 510(k) Clearance for Halcyon and Ethos Radiotherapy Systems Featuring HyperSight Imaging Solution and Announces First Patient Treatment

  2/2/2023

  Varian, a Siemens Healthineers company, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), as well as CE mark, for Halcyon® and Ethos™ radiotherapy systems featuring Varian's HyperSight™ imaging solution.

• Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding Composition of Matter for Family 1 Psilocybin Analogs

  2/2/2023

  Mindset Pharma Inc. announced today that the United States Patent and Trademark Office (“USPTO”) has granted allowance for another of Mindset’s Family 1 patent applications, number 17/743,718, titled “Psilocin Derivatives As Serotonergic Psychedelic Agents for the Treatment of CNS Disorders.”